enGene Holdings Inc. (NASDAQ:ENGN) Short Interest Update

enGene Holdings Inc. (NASDAQ:ENGN) experienced a notable decline in short interest during February. As of February 28th, the total short interest was reported at 60,300 shares, reflecting a steep decrease of 31.9% from the February 13th figure of 88,500 shares. Currently, only about 0.3% of the company's shares are sold short. Given an average daily trading volume of 131,100 shares, the days-to-cover ratio stands at 0.5 days.

enGene Stock Performance

On Friday, shares of enGene opened at $5.40. Over the past year, the stock has hit a low of $4.42 and a high of $18.40. enGene has a debt-to-equity ratio of 0.08, with a current ratio and quick ratio both at 16.87. The 50-day simple moving average is $6.51, and the 200-day simple moving average is $7.11. The company's market capitalization is approximately $275.28 million, with a price-to-earnings ratio of -9.31 and a beta of -0.61.

The company released its quarterly earnings results on December 19th, reporting an earnings per share (EPS) of ($0.34), which exceeded analysts' consensus estimates of ($0.40) by $0.06. Analysts predict that enGene will post an EPS of -1.56 for the current fiscal year.

Analyst Ratings and Targets

Several equities research analysts have recently weighed in on shares of enGene. On February 18th, Piper Sandler initiated coverage of enGene, assigning an "overweight" rating with a price target of $26.00. Conversely, UBS Group downgraded enGene from a "buy" to a "neutral" rating, while also lowering their price target from $34.00 to $7.00 on February 14th. Raymond James began coverage on enGene on November 27th, giving it an "outperform" rating with a price target of $23.00. In a separate note on December 23rd, JMP Securities maintained a "market outperform" rating with a target price of $18.00. Additionally, Citizens JMP upgraded enGene to a "strong-buy" rating on November 18th. Among analysts, one has rated the stock as a hold, eight suggest a buy, and one marks it as a strong buy. MarketBeat indicates that enGene holds a consensus rating of "Buy" and an average target price of $25.22.

Institutional Investors Activity

Recently, various institutional investors and hedge funds have adjusted their positions in enGene. Fcpm Iii Services B.V. increased its stake in enGene by 11.0% during the fourth quarter, now owning 9,632,561 shares valued at $64,057,000 after acquiring an additional 954,610 shares. Similarly, VR Adviser LLC raised its holdings by 41.5% during the same period, obtaining 5,046,414 shares worth $33,559,000, adding 1,480,573 shares. Deep Track Capital LP increased its holdings by 74.8%, acquiring an additional 1,949,942 shares, leading to a total of 4,557,575 shares valued at $30,308,000. Blue Owl Capital Holdings LP added 101,006 shares to own 3,159,975 shares worth $21,014,000, which reflects a growth of 3.3%. Lastly, Point72 Asset Management L.P. boosted its holdings by 84.7%, now owning 1,224,797 shares valued at $8,145,000. Currently, 64.16% of enGene's shares are owned by institutional investors.

Company Overview

enGene Holdings Inc. operates through its subsidiary enGene, Inc. as a clinical-stage biotechnology company focused on developing genetic medicines. Their lead product, EG-70 (detalimogene voraplasmid), is a non-viral immunotherapy targeting non-muscle invasive bladder cancer patients with carcinoma-in-situ who do not respond to Bacillus Calmette-Guérin treatment.

Conclusion

This summary serves to provide an overview of the recent trends and performance relating to enGene Holdings Inc. The movements of short interest, institutional investments, and analyst ratings reflect the company's position and expectations in the market.

enGene, short, interest